Lytix Biopharma AS (OSL:LYTIX) FCF Margin % : -4,402.65% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lytix Biopharma AS's Free Cash Flow for the three months ended in Dec. 2024 was kr-16.60 Mil. Lytix Biopharma AS's Revenue for the three months ended in Dec. 2024 was kr0.38 Mil. Therefore, Lytix Biopharma AS's FCF Margin % for the quarter that ended in Dec. 2024 was -4,402.65%.

As of today, Lytix Biopharma AS's current FCF Yield % is -20.46%.

The historical rank and industry rank for Lytix Biopharma AS's FCF Margin % or its related term are showing as below:

OSL:LYTIX' s FCF Margin % Range Over the Past 10 Years
Min: -811566.67 Med: -2405.86 Max: -231.04
Current: -632.05

During the past 7 years, the highest FCF Margin % of Lytix Biopharma AS was -231.04%. The lowest was -811566.67%. And the median was -2405.86%.

OSL:LYTIX's FCF Margin % is ranked worse than
72.21% of 1011 companies
in the Biotechnology industry
Industry Median: -137.96 vs OSL:LYTIX: -632.05

Lytix Biopharma AS FCF Margin % Historical Data

The historical data trend for Lytix Biopharma AS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lytix Biopharma AS FCF Margin % Chart

Lytix Biopharma AS Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-811,566.67

-231.04

-478.47

-2,405.86

-632.10

Lytix Biopharma AS Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-231.00	-	-7,162.34	-4,402.65

Competitive Comparison of Lytix Biopharma AS's FCF Margin %

For the Biotechnology subindustry, Lytix Biopharma AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lytix Biopharma AS's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Lytix Biopharma AS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lytix Biopharma AS's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-70.372	/	11.133
	=	-632.10 %

Lytix Biopharma AS's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-16.598	/	0.377
	=	-4,402.65 %

Lytix Biopharma AS FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lytix Biopharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (OSL:LYTIX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sandakerveien 138, Oslo, NOR, 0484

Website

https://www.lytixbiopharma.com

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.

Lytix Biopharma AS Headlines

No Headlines